Results 231 to 240 of about 2,313,243 (300)

APOBEC3B Does Not Promote Tumor Progression in Tp53 Hemizygous Mice. [PDF]

Cancer Rep (Hoboken)
Horisawa Y, Matsumoto T, Takeda J, Tashiro Y, Nomura R, Takeuchi S, Kawai Y, Kazuma Y, Konishi Y, Yamazaki H, Matsui H, Shirakawa K, Takaori-Kondo A.   +12 more
europepmc   +1 more source

Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening. [PDF]

Vaccines (Basel)
Zhang J, Fang F, Zhang Y, Han X, Wang Y, Yin Q, Sun K, Zhou H, Qin H, Zhao D, Tai W, Zhang J, Zhang Z, Yang T, Wei Y, Zhang S, Li S, Li M, Zhao G.   +18 more
europepmc   +1 more source

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

Cancer Communications, EarlyView.
Abstract Background Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer.
Jinghan Zhu, Yixiao Xiong, Yuxin Zhang, Huifang Liang, Kun Cheng, Yuanxiang Lu, Guangzhen Cai, Yang Wu, Yunhui Fan, Xiaoping Chen, Hong Zhu, Zeyang Ding, Wanguang Zhang   +12 more
wiley   +1 more source

ATT-Myc Transgenic Mouse Model and Gene Expression Identify Genotoxic and Non-Genotoxic Chemicals That Accelerating Liver Tumor Growth in Short-Term Toxicity. [PDF]

Biomedicines
Elalfy M, Borlak J, Aljazzar AJ, Elhadidy MG.   +3 more
europepmc   +1 more source

Protective compunds in animal models of trigeminal activation and neurodegeneration [PDF]

, 2009
Vámos Enikő
core  

Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition

Chemistry &Biodiversity, EarlyView.
ABSTRACT Alzheimer's disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ).
Najlaa Hamed Almohmadi, Hayder M. Al‐Kuraishy, Ali I. Al‐Gareeb, Ali K. Albuhadily, Morkoss M. Fakhry, Athanasios Alexiou, Marios Papadakis, Gaber El‐Saber Batiha   +7 more
wiley   +1 more source

Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights. [PDF]

Pharmacol Res Perspect
Tung CW, Chan SC, Cheng PH, Chen YC, Wu PM, Lin WC, Chen RJ, Huang BM, Yang SH.   +8 more
europepmc   +1 more source

Peptidomimetics Targeting the Amyloidogenicity of Nucleophosmin 1 Mutations in Acute Myeloid Leukemia

ChemBioChem, Accepted Article.
Nucleophosmin 1(NPM1) is an abundant human protein endowed with many functions whose dysregulation leads to various cancers and mutations are relevant in Acute Myeloid Leukemia (AML). In the wild type form, pentameric NPM1 resides mainly in the nucleolus even if it shuttles toward the cytosol exerting its chaperon function, conversely in AML‐mutated ...
Daniele Florio, Sara La Manna, Giada Raffaella Fiore, Valentina Roviello, Giuliano Castellano, Sossio Fabio Graziano, Anna Maria Malfitano, Daniela Marasco   +7 more
wiley   +1 more source

tRF^Ala-AGC-3-M8 attenuates neuroinflammation and neuronal damage in Alzheimer's disease via the EphA7-ERK_1/2-p70S6K signaling pathway. [PDF]

Alzheimers Res Ther
Deng Z, Li Y, Chi W, Zhang W, Li F, Ling L.   +5 more
europepmc   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source